234 related articles for article (PubMed ID: 25193892)
41. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
Kobayashi H; Abe M; Okada K; Tei R; Maruyama N; Kikuchi F; Higuchi T; Soma M
Nutrients; 2015 May; 7(5):3783-95. PubMed ID: 25988769
[TBL] [Abstract][Full Text] [Related]
42. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
[TBL] [Abstract][Full Text] [Related]
43. [Frequency of anaemia and indications for treatment with epoetin in chronic renal failure at the pre-dialysis stage].
Jungers PY; Nguyen-Khoa T; Joly D; Choukroun G; Massy ZA; Jungers P
Presse Med; 2003 Feb; 32(5):212-6. PubMed ID: 12610461
[TBL] [Abstract][Full Text] [Related]
44. A Hypoxia-Inducible Factor Stabilizer Improves Hematopoiesis and Iron Metabolism Early after Administration to Treat Anemia in Hemodialysis Patients.
Ogawa C; Tsuchiya K; Tomosugi N; Maeda K
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998272
[TBL] [Abstract][Full Text] [Related]
45. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.
Kawai T; Kusano Y; Yamada K; Ueda C; Kawai A; Masaki T
J Artif Organs; 2019 Jun; 22(2):146-153. PubMed ID: 30426250
[TBL] [Abstract][Full Text] [Related]
46. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
[TBL] [Abstract][Full Text] [Related]
47. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
[TBL] [Abstract][Full Text] [Related]
48. A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients.
Toida T; Sato Y; Shibata N; Kitamura K; Fujimoto S
Blood Purif; 2014; 38(3-4):174-9. PubMed ID: 25502179
[TBL] [Abstract][Full Text] [Related]
49. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.
Gaweda AE; Goldsmith LJ; Brier ME; Aronoff GR
Clin J Am Soc Nephrol; 2010 Apr; 5(4):576-81. PubMed ID: 20110344
[TBL] [Abstract][Full Text] [Related]
50. The relationship between depressive symptoms and erythropoietin resistance in stable hemodialysis patients with adequate iron stores.
Afsar B
Int J Artif Organs; 2013 May; 36(5):314-9. PubMed ID: 23645578
[TBL] [Abstract][Full Text] [Related]
51. Anemia in chronic kidney disease: causes, diagnosis, treatment.
Nurko S
Cleve Clin J Med; 2006 Mar; 73(3):289-97. PubMed ID: 16548452
[TBL] [Abstract][Full Text] [Related]
52. [Current issues in erythropoietin therapy of renal anemia].
Zakar G
Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
[TBL] [Abstract][Full Text] [Related]
53. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.
Santos EJF; Hortegal EV; Serra HO; Lages JS; Salgado-Filho N; Dos Santos AM
Braz J Med Biol Res; 2018; 51(7):e7288. PubMed ID: 29742267
[TBL] [Abstract][Full Text] [Related]
54. Serum hepcidin in haemodialysis patients: associations with iron status and microinflammation.
Xu Y; Ding XQ; Zou JZ; Liu ZH; Jiang SH; Chen YM
J Int Med Res; 2011; 39(5):1961-7. PubMed ID: 22118000
[TBL] [Abstract][Full Text] [Related]
55. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
[TBL] [Abstract][Full Text] [Related]
56. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents.
Tessitore N; Girelli D; Campostrini N; Bedogna V; Pietro Solero G; Castagna A; Melilli E; Mantovani W; De Matteis G; Olivieri O; Poli A; Lupo A
Nephrol Dial Transplant; 2010 Dec; 25(12):3996-4002. PubMed ID: 20538788
[TBL] [Abstract][Full Text] [Related]
57. Serum hepcidin in inflammatory bowel diseases: biological and clinical significance.
Bergamaschi G; Di Sabatino A; Albertini R; Costanzo F; Guerci M; Masotti M; Pasini A; Massari A; Campostrini N; Corbella M; Girelli D; Corazza GR
Inflamm Bowel Dis; 2013 Sep; 19(10):2166-72. PubMed ID: 23867871
[TBL] [Abstract][Full Text] [Related]
58. Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
Barosi G; Merlo C; Palestra P; Liberato NL; Guarnone R; Di Dio F; Piazza V; Salvadeo A
Acta Haematol; 1993; 90(1):13-8. PubMed ID: 8237268
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients.
Mohammadpour AH; Nazemian F; Khaiat MH; Tafaghodi M; Salari P; Charkazi S; Naghibi M; Shamsara J
Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):73-8. PubMed ID: 24434385
[TBL] [Abstract][Full Text] [Related]
60. Effects of Long-Term Erythropoiesis-Stimulating Agents on Iron Metabolism in Patients on Hemodialysis.
Onuma S; Honda H; Kobayashi Y; Yamamoto T; Michihata T; Shibagaki K; Yuza T; Hirao K; Tomosugi N; Shibata T
Ther Apher Dial; 2015 Dec; 19(6):582-9. PubMed ID: 26481900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
